Management of Neonatal Hyperbilirubinemia

Introduction to the Bhutani Nomogram

The American Academy of Pediatrics recommends using the Bhutani nomogram to risk-stratify newborns ≥35 weeks gestation by plotting hour-specific bilirubin values against postnatal age to determine follow-up timing and phototherapy decisions 1.

The Bhutani nomogram divides infants into four distinct risk zones based on predischarge total serum bilirubin (TSB) or transcutaneous bilirubin (TcB) measurements plotted against the infant's exact age in hours: high-risk zone (≥95th percentile), high-intermediate risk zone (75th-94th percentile), low-intermediate risk zone (40th-74th percentile), and low-risk zone (<40th percentile) 1, 2.
Infants in the high-risk zone require immediate intervention and close follow-up 2, 3.

The nomogram applies specifically to infants ≥36 weeks gestational age with birth weight ≥2000g, or infants ≥35 weeks gestational age with birth weight ≥2500g 1.

All bilirubin levels must be plotted using the infant's age in hours, never in days, to avoid common and dangerous errors that can lead to inappropriate risk stratification 1.

Identify high-risk features that increase the likelihood of severe hyperbilirubinemia, including predischarge bilirubin in the high-risk zone on the nomogram, jaundice observed in the first 24 hours, blood group incompatibility with positive Coombs test or other hemolytic disease, gestational age 35-36 weeks, previous sibling who received phototherapy, cephalohematoma or significant bruising, exclusive breastfeeding with poor nursing and excessive weight loss, and East Asian race 1, 2, 5.

The American Academy of Pediatrics provides specific follow-up schedules based on discharge timing, with infants discharged before 24 hours requiring follow-up within 72 hours, those discharged between 24-47.9 hours requiring follow-up within 96 hours, and those discharged between 48-72 hours requiring follow-up within 120 hours 2, 3.

When bilirubin is rising rapidly (>0.2 mg/dL/hour after 24 hours) or unexplained by clinical assessment, obtain blood type and Coombs test, complete blood count with peripheral smear, direct or conjugated bilirubin, reticulocyte count, and G6PD testing when TSB approaches exchange levels or fails to respond to phototherapy 1, 4, 5.

Phototherapy should be initiated when TSB reaches or exceeds the phototherapy threshold for the infant's age and risk category, with the American Academy of Pediatrics providing separate nomograms for phototherapy initiation based on gestational age at birth, presence of neurotoxicity risk factors, and hour-specific bilirubin levels 1, 2, 4, 5.

Once phototherapy is initiated, clinical impact should be evident within 4-6 hours, with an expected decrease of >2 mg/dL in serum bilirubin concentration, and TSB should be measured to verify efficacy after starting treatment 4, 5.

All hospitals must provide written and verbal information to parents, including explanation of jaundice, need to monitor infants for jaundice, specific advice on how monitoring should be performed, and when to seek immediate medical attention 2, 3, 5.